Since mafenide is metabolized to a carbonic anhydrase inhibitor, metabolic acidosis could occur.
Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.L36773 In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations. In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements.L44251
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Mafenide is combined with Prilocaine. |
| Dapsone | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Mafenide. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Mafenide. |
| Benzylpenicillin | Mafenide may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Mafenide. |
| Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen | The therapeutic efficacy of Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen can be decreased when used in combination with Mafenide. |
| Insulin human | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin human. |
| Insulin lispro | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin lispro. |
| Insulin glargine | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin glargine. |
| Insulin pork | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin pork. |
| Insulin aspart | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin aspart. |
| Insulin detemir | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin detemir. |
| Insulin glulisine | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin glulisine. |
| NN344 | The risk or severity of hypoglycemia can be increased when Mafenide is combined with NN344. |
| Insulin beef | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin beef. |
| Insulin degludec | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin degludec. |
| Insulin argine | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin argine. |
| Insulin peglispro | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin peglispro. |
| Insulin tregopil | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin tregopil. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Mafenide. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Mafenide. |
| Insulin icodec | The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin icodec. |